glaukos corp - GKOS
GKOS
Close Chg Chg %
105.07 2.70 2.57%
Open Market
107.77
+2.70 (2.57%)
Volume: 197.29K
Last Updated:
Mar 31, 2026, 2:11 PM EDT
Company Overview: glaukos corp - GKOS
GKOS Key Data
| Open $106.66 | Day Range 105.03 - 108.90 |
| 52 Week Range 73.16 - 130.23 | Market Cap $6.10B |
| Shares Outstanding 58.08M | Public Float 55.47M |
| Beta 0.70 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.27 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 726.98K |
GKOS Performance
| 1 Week | 1.77% | ||
| 1 Month | -12.78% | ||
| 3 Months | -7.00% | ||
| 1 Year | 25.53% | ||
| 5 Years | 28.11% |
GKOS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
14
Full Ratings ➔
About glaukos corp - GKOS
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.
GKOS At a Glance
Glaukos Corp.
One Glaukos Way
Aliso Viejo, California 92656
| Phone | 1-949-367-9600 | Revenue | 507.44M | |
| Industry | Medical Specialties | Net Income | -187,691,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 32.325% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,094 | |
| View SEC Filings |
GKOS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.725 |
| Price to Book Ratio | 9.896 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -141.595 |
| Enterprise Value to Sales | 12.386 |
| Total Debt to Enterprise Value | 0.017 |
GKOS Efficiency
| Revenue/Employee | 463,840.951 |
| Income Per Employee | -171,563.985 |
| Receivables Turnover | 4.672 |
| Total Asset Turnover | 0.516 |
GKOS Liquidity
| Current Ratio | 4.69 |
| Quick Ratio | 4.062 |
| Cash Ratio | 2.753 |
GKOS Profitability
| Gross Margin | 77.49 |
| Operating Margin | -17.092 |
| Pretax Margin | -38.042 |
| Net Margin | -36.988 |
| Return on Assets | -19.089 |
| Return on Equity | -26.378 |
| Return on Total Capital | -24.609 |
| Return on Invested Capital | -23.024 |
GKOS Capital Structure
| Total Debt to Total Equity | 16.238 |
| Total Debt to Total Capital | 13.969 |
| Total Debt to Total Assets | 11.452 |
| Long-Term Debt to Equity | 15.831 |
| Long-Term Debt to Total Capital | 13.62 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Glaukos Corp - GKOS
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 282.86M | 314.71M | 383.48M | 507.44M | |
Sales Growth
| -3.79% | +11.26% | +21.85% | +32.33% | |
Cost of Goods Sold (COGS) incl D&A
| 71.40M | 78.00M | 96.41M | 114.23M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 35.95M | 37.98M | 39.92M | 42.34M | |
Depreciation
| 11.03M | 13.07M | 15.22M | 15.22M | |
Amortization of Intangibles
| 24.91M | 24.91M | 24.70M | 27.13M | |
COGS Growth
| +3.41% | +9.24% | +23.61% | +18.48% | |
Gross Income
| 211.46M | 236.72M | 287.07M | 393.22M | |
Gross Income Growth
| -6.00% | +11.94% | +21.27% | +36.98% | |
Gross Profit Margin
| +74.76% | +75.22% | +74.86% | +77.49% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 313.77M | 360.42M | 395.21M | 479.95M | |
Research & Development
| 123.27M | 138.77M | 136.43M | 150.61M | |
Other SG&A
| 190.50M | 221.65M | 258.78M | 329.33M | |
SGA Growth
| +12.94% | +14.86% | +9.65% | +21.44% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (20.00M) | 5.00M | 14.23M | 112.87M | |
EBIT after Unusual Expense
| (82.31M) | (128.70M) | (122.37M) | (199.60M) | |
Non Operating Income/Expense
| (2.40M) | 8.61M | 4.82M | 11.19M | |
Non-Operating Interest Income
| 2.38M | 9.16M | 11.11M | 10.71M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 13.72M | 13.63M | 28.05M | 4.63M | |
Interest Expense Growth
| +2.60% | -0.63% | +105.77% | -83.48% | |
Gross Interest Expense
| 13.72M | 13.63M | 28.05M | 4.63M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (98.43M) | (133.73M) | (145.60M) | (193.04M) | |
Pretax Income Growth
| -99.79% | -35.86% | -8.88% | -32.58% | |
Pretax Margin
| -34.80% | -42.49% | -37.97% | -38.04% | |
Income Tax
| 766.00K | 934.00K | 771.00K | (5.35M) | |
Income Tax - Current - Domestic
| 128.00K | 239.00K | 307.00K | 176.00K | |
Income Tax - Current - Foreign
| 693.00K | 815.00K | 680.00K | 960.00K | |
Income Tax - Deferred - Domestic
| (73.00K) | (120.00K) | (216.00K) | (6.49M) | |
Income Tax - Deferred - Foreign
| - | - | - | 18.00K | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (99.19M) | (134.66M) | (146.37M) | (187.69M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (99.19M) | (134.66M) | (146.37M) | (187.69M) | |
Net Income Growth
| -100.02% | -35.75% | -8.70% | -28.23% | |
Net Margin Growth
| -35.07% | -42.79% | -38.17% | -36.99% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (99.19M) | (134.66M) | (146.37M) | (187.69M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (99.19M) | (134.66M) | (146.37M) | (187.69M) | |
EPS (Basic)
| -2.0908 | -2.7804 | -2.7746 | -3.2819 | |
EPS (Basic) Growth
| -95.71% | -32.98% | +0.21% | -18.28% | |
Basic Shares Outstanding
| 47.44M | 48.43M | 52.76M | 57.19M | |
EPS (Diluted)
| -2.0908 | -2.7804 | -2.7746 | -3.2819 | |
EPS (Diluted) Growth
| -95.71% | -32.98% | +0.21% | -18.28% | |
Diluted Shares Outstanding
| 47.44M | 48.43M | 52.76M | 57.19M | |
EBITDA
| (66.37M) | (85.72M) | (68.22M) | (44.39M) | |
EBITDA Growth
| -259.69% | -29.16% | +20.42% | +34.93% | |
EBITDA Margin
| -23.46% | -27.24% | -17.79% | -8.75% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 139.615 | |
| Number of Ratings | 14 | Current Quarters Estimate | -0.211 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -0.543 | |
| Last Quarter’s Earnings | -0.29 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.90 | Next Fiscal Year Estimate | 0.434 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 13 | 13 | 13 |
| Mean Estimate | -0.21 | -0.09 | -0.54 | 0.43 |
| High Estimates | -0.09 | -0.01 | -0.39 | 0.74 |
| Low Estimate | -0.28 | -0.19 | -0.86 | -0.01 |
| Coefficient of Variance | -28.08 | -54.31 | -25.57 | 54.81 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 14 | 14 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 1 | 1 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Glaukos Corp - GKOS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Glaukos Corp - GKOS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Dec 12, 2025 | Gilbert H. Kliman Director | 39,905 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $24.69 per share | 985,254.45 |
| Dec 12, 2025 | Gilbert H. Kliman Director | 34,905 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $107.27 per share | 3,744,259.35 |
| Dec 12, 2025 | Gilbert H. Kliman Director | 10,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Thomas William Burns CHAIRMAN & CEO; Director | 157,618 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $98.42 per share | 15,512,763.56 |
| Apr 4, 2025 | Thomas William Burns CHAIRMAN & CEO; Director | 153,559 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $97.09 per share | 14,909,043.31 |
| Apr 4, 2025 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | 82,088 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $98.42 per share | 8,079,100.96 |
| Apr 4, 2025 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | 81,604 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $97.09 per share | 7,922,932.36 |
| Apr 4, 2025 | Joseph E. Gilliam PRESIDENT & COO | 109,768 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $97.09 per share | 10,657,375.12 |
| Apr 4, 2025 | Alex Thurman SVP & CHIEF FINANCIAL OFFICER | 53,120 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $97.09 per share | 5,157,420.80 |